These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20484614)

  • 1. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
    J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
    Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
    J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
    Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
    Eckermann G; Lahu G; Nassr N; Bethke TD
    J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
    Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
    J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
    Bethke TD; Böhmer GM; Hermann R; Hauns B; Fux R; Mörike K; David M; Knoerzer D; Wurst W; Gleiter CH
    J Clin Pharmacol; 2007 Jan; 47(1):26-36. PubMed ID: 17192499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
    Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
    Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of roflumilast.
    Lahu G; Nassr N; Hünnemeyer A
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
    Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
    Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
    Nassr N; Huennemeyer A; Herzog R; von Richter O; Hermann R; Koch M; Duffy K; Zech K; Lahu G
    Br J Clin Pharmacol; 2009 Oct; 68(4):580-7. PubMed ID: 19843061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K
    J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of roflumilast in children and adolescents.
    Neville KA; Szefler SJ; Abdel-Rahman SM; Lahu G; Zech K; Herzog R; Bethke TD; Gleason MC; Kearns GL
    J Clin Pharmacol; 2008 Aug; 48(8):978-85. PubMed ID: 18508947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 17. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A; Marostica E; Gardiner P; Watz H; Lahu G
    Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.